Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Sponsor: NGM Biopharmaceuticals, Inc

Sponsor score: 0
Inactive

ClinicalTrials ID:NCT04913337

Patient View

This clinical trial evaluates NGM707, alone and with pembrolizumab, in patients with advanced or metastatic solid tumors. Eligible participants must have progressed on or be intolerant to standard therapies, possess adequate organ function, and have a performance status of 0 or 1. NGM707 and pembrolizumab are administered intravenously every 3 weeks, with multiple dose levels assessed.

Patient Parameters

Program Overview

Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Eligibility Criteria

Inclusion Criteria

  • Histologically or cytologically documented locally advanced or metastatic solid tumor malignancy.
  • Progressed or was intolerant to all available therapies known to confer clinical benefit appropriate for their tumor type, and for which the patient was eligible and willing to receive, or refused SOC treatments that are perceived to have marginal clinical benefit.
  • Adequate bone marrow, kidney and liver function.
  • Performance status of 0 or 1.
  • Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade 1 except for AEs not constituting a safety risk by Investigator judgement.

Exclusion Criteria

  • Prior treatment targeting ILT2 and/or ILT4 or targeting HLA-G.

Get This Program In Your Inbox

You can sign up and apply your patients for this program.